Search

Your search keyword '"Nicod, Laurent"' showing total 30 results
Start Over Author "Nicod, Laurent" Database OpenAIRE
30 results on '"Nicod, Laurent"'

1. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

Author

Klimek, Ludger, Pfaar, Dr O., Worm, Margitta M., Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus W., Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana O., Bavbek, S., Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, A., Vogelberg, Christian, Firinu, Davide, Kauppi, P., Kolios, Antonios G.A., Kothari, Akash, Matucci, Andrea, Palomares, Óscar, Szépfalusi, Zsolt, Hötzenecker, Wolfram, Rosenkranz, A. R., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, Thomas, Kleine-Tebbe, Jörg, Lau, S., Maurer, Marcus, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus Friedrich, Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, Kirsten, Schlenter, Wolfgang W., Ring, Johannnes, Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent Pierre, Schmid-Grendelmeier, Peter D., Idzko, Marco, Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin M., Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, François R., Schwarze, Jürgen, O'Mahony, Liam, Knol, Edward Frank, del Giacco, Stefano R., Chivato Pérez, T., Bousquet, Jean J., Zuberbier, Thorsten, Akdis, Cezmi A., Jutel, Marek, MACVIA-France, Montpellier, Centre de recherche en épidémiologie et santé des populations (CESP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)

Subjects
SARS-CoV-2, [SDV]Life Sciences [q-bio], Benralizumab, Omalizumab, Dupilumab, Reslizumab, Covid-19, ComputingMilieux_MISCELLANEOUS, Mepolizumab, Telemedicine
Abstract

International audience

Published
2020

2. Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA GroupA in cooperation with the Austrian ARIA GroupB, the Swiss ARIA GroupC, German Society for Applied Allergology (AEDA)D, German Society for Allergology and Clinical Immunology (DGAKI)E, Society for Pediatric Allergology (GPA)F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHCG and the European Academy of Allergy and Clinical Immunology (EAACI)H

Author

Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, Petra, Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert, Nemat, Katja, Czech, Wofgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Akdis, Cezmi, Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo, Spertin, FranÇois, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean, and Zuberbier, Torsten

Subjects
610 Medicine & health
Abstract

No abstract available.

Published
2020
Full Text
View/download PDF

3. Allergen immunotherapy in the current COVID-19 pandemic - A position paper of the AeDA, ARIA, EAACI, DGAKI and GPA

Author

Klimek, Ludger, Pfaar, Dr O., Worm, Margitta M., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Mar, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, P., Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, Kirsten, Schlenter, Wolfgang W., Ring, Johannnes, Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Akdis, Cezmi A., Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter D., Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean J., Zuberbier, Torsten, Rheinische Friedrich-Wilhelms-Universität Bonn, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
SLIT, [SDV]Life Sciences [q-bio], COVID-19, Antiviral immunity, SCIT, ComputingMilieux_MISCELLANEOUS, Allergen immunotherapy
Abstract

International audience

Published
2020

4. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie

Author

Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thohomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szepfalusi, Zsolt, Pohl, Wolfgang, Hoetzenecker, Wolfram, Rosenkranz, Alexander R., Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Joerg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Moesges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus F., Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ringa, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Muelleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje-H, Horak, Fritz, Woehrl, Stefan, Niederberger-Leppin, Verena, Pali-Schoell, Isabella, Pohlg, Wolfgang, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Muebeccel, Matricardi, Paolo M., Spertini, Francois, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Juergen, O'Mahony, Liam, Knol, Edward F., del Giacco, Stefano, Chivato Perez, Tomas, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek

Published
2020

5. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)

Author

Pfaar, Oliver, Klimek, Ludger, Worm, Margitta M., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, T., Kleine-Tebbe, Jörg, Lau, S., Maurer, Marcus, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, P., Rabe, K., Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, K., Schlenter, Wolfgang W., Ring, J., Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Akdis, Cezmi A., Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent Pierre, Schmid-Grendelmeier, Peter D., Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin M., Taube, C., Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean J., Zuberbier, Thorsten, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), FMC VIA LR, 371, avenue Doyen-Gaston-Giraud, 34295 Montpellier cedex 5, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), and Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)

Subjects
[SHS.LANGUE]Humanities and Social Sciences/Linguistics, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

6. Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration

Author

Agusti, Alvar, Faner, Rosa, Donaldson, Gavin, Heuvelin, Elise, Breyer-Kohansal, Robab, Melén, Erik, Maitland-van der Zee, Anke H., Vestbo, J. rgen, Allinson, James P., Vanfleteren, Lowie E. G. W., van den Berge, Maarten, Adcock, Ian M., Lahousse, Lies, Brusselle, Guy, Wedzicha, Jadwiga A., Maitland-van der Zee, Anke-Hilse, Alter, Peter, Barbe, Ferran, Brightling, Christopher E., Breyer, Marie-Kathrin, Burghuber, Otto C., Casas, Maribel, Chung, Kian Fan, Cosío, Borja G., Crispi, Fatima, Batlle, Jordi de, Fitting, Jean-William, Garcia, Judith, Hallberg, Jenny, Hartl, Sylvia, Jarvis, Deborah, Mathioudakis, Alexander, Nicod, Laurent, Papi, Alberto, Ritchie, Andrew, Sigsgaard, Torben, Sterk, Peter J., Ullman, Anders, Paediatric Pulmonology, Pulmonology, and APH - Personalized Medicine

Subjects
IMPACT, Respiratory System, CHILDHOOD, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, PRECISION MEDICINE, Pulmonary Medicine, 030212 general & internal medicine, Registries, Child, Lung, Lung function, Societies, Medical, RISK, Geography, 11 Medical And Health Sciences, Middle Aged, 3. Good health, Europe, Interinstitutional Relations, Current members of the CADSET Clinical Research Collaboration, Child, Preschool, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, PRETERM BIRTH, Adolescent, Interdisciplinary Research, Pulmonary disease, 03 medical and health sciences, Young Adult, medicine, Humans, Intensive care medicine, LUNG-FUNCTION TRAJECTORIES, Aged, business.industry, Infant, Newborn, Infant, NATURAL-HISTORY, Precision medicine, LIFE, Airway Obstruction, Clinical research, 030228 respiratory system, ASTHMA, business, Airway, on behalf of the CADSET Clinical Research Collaboration
Abstract

A recent editorial in the European Respiratory Journal highlighted the strategic importance of the Clinical Research Collaborations (CRCs) launched in 2013 by the European Respiratory Society (ERS) [1]. These have the aim of 1) promoting the exchange of research ideas among clinicians and affiliated scientists in Europe and/or globally; 2) building an infrastructure for prospective clinical research; 3) securing additional funding through national and European Union funding streams; and 4) facilitating the planning, implementation, evaluation and publication of clinical and translational studies at pan-European level and beyond. So far, there are currently 17 ongoing CRCs that cover eight major respiratory disease domains (airway diseases, interstitial lung diseases, pulmonary vascular diseases, sleep and breathing disorders, respiratory critical care, paediatric respiratory diseases, respiratory infections and thoracic oncology), all of them linked to one or more ERS assemblies [2–12]. CADSET, an acronym that stands for “Chronic Airway Diseases Early Stratification”, is the latest addition to the list of ongoing CRCs (www.ersnet.org/research/clinical-research-collaborations). This editorial presents the rationale, goals and research strategy for CADSET.

Published
2019

7. MR Volumetry of Lung Nodules: A Pilot Study

Author

Delacoste, Jean, Dunet, Vincent, Dournes, Gael, Lovis, Alban, Rohner, Chantal, Elandoy, Christel, Simons, Julien, Long, Olivier, Piccini, Davide, Stuber, Matthias, Prior, John O., Nicod, Laurent, and Beigelman-Aubry, Catherine

Subjects
volumetry, segmentation, Medicine, UTE, Brief Research Report, MRI, lung, nodules
Abstract

Introduction: Computed tomography (CT) is currently the reference modality for the detection and follow-up of pulmonary nodules. While 2D measurements are commonly used in clinical practice to assess growth, increasingly 3D volume measurements are being recommended. The goal of this pilot study was to evaluate preliminarily the capabilities of 3D MRI using ultra-short echo time for lung nodule volumetry, as it would provide a radiation-free modality for this task. Material and Methods: Artificial nodules were manufactured out of Agar and measured using an ultra-short echo time MRI sequence. CT data were also acquired as a reference. Image segmentation was carried out using an algorithm based on signal intensity thresholding (SIT). For comparison purposes, we also performed manual slice by slice segmentation. Volumes obtained with MRI and CT were compared. Finally, the volumetry of a lung nodule was evaluated in one human subject in comparison with CT. Results: Using the SIT technique, minimal bias was observed between CT and MRI across the entire range of volumes (2%) with limits of agreement below 14%. Comparison of manually segmented MRI and CT resulted in a larger bias (8%) and wider limits of agreement (-23% to 40%). In vivo, nodule volume differed of

Published
2019

8. Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung

Author

Mouraux, Stéphane, Bernasconi, Eric, Pattaroni, Céline, Koutsokera, Angela, Aubert, John-David, Claustre, Johanna, Pison, Christophe, Royer, Pierre-Joseph, Magnan, Antoine, Kessler, Romain, Benden, Christian, Soccal, Paola M, Marsland, Benjamin J, Nicod, Laurent P, SysCLAD Consortium, University of Zurich, and Bernasconi, Eric

Subjects
2403 Immunology, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health, 10045 Clinic for Otorhinolaryngology, 10178 Clinic for Pneumology
Published
2018

9. Blood gene expression predicts bronchiolitis obliterans syndrome

Author

Danger, Richard, Royer, Pierre-Joseph, Reboulleau, Damien, Durand, Eugenie, Loy, Jennifer, Tissot, Adrien, Lacoste, Philippe, Roux, Antoine, Reynaud-Gaubert, Martine, Gomez, Carine, Kessler, Romain, Mussot, Sacha, Dromer, Claire, Brugière, Olivier, Mornex, Jean-Francois, Guillemain, Romain, Dahan, Marcel, Knoop, Christiane, Botturi, Karine, Foureau, Aurore, Pison, Christophe, Koutsokera, Angela, Nicod, Laurent P., Brouard, Sophie, Magnan, Antoine, Cohort of Lung Transplantation, and Systems prediction of Chronic Lung Allograft Dysfunction

Subjects
maladie pulmonaire, lung transplantation, bronchiolitis obliterans syndrome, gene expression, biomarkers, blood, Pneumologie et système respiratoire, sang, Pulmonology and respiratory tract, biomarqueur, humanities, expression des gènes
Abstract

Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunction, leads to poor long-term survival after lung transplantation. Identifying predictors of BOS is essential to prevent the progression of dysfunction before irreversible damage occurs. By using a large set of 107 samples from lung recipients, we performed microarray gene expression profiling of whole blood to identify early biomarkers of BOS, including samples from 49 patients with stable function for at least 3 years, 32 samples collected at least 6 months before BOS diagnosis (prediction group), and 26 samples at or after BOS diagnosis (diagnosis group). An independent set from 25 lung recipients was used for validation by quantitative PCR (13 stables, 11 in the prediction group, and 8 in the diagnosis group). We identified 50 transcripts differentially expressed between stable and BOS recipients. Three genes, namely POU class 2 associating factor 1 (POU2AF1), T-cell leukemia/lymphoma protein 1A (TCL1A), and B cell lymphocyte kinase, were validated as predictive biomarkers of BOS more than 6 months before diagnosis, with areas under the curve of 0.83, 0.77, and 0.78 respectively. These genes allow stratification based on BOS risk (log-rank test p < 0.01) and are not associated with time posttransplantation. This is the first published large-scale gene expression analysis of blood after lung transplantation. The three-gene blood signature could provide clinicians with new tools to improve follow-up and adapt treatment of patients likely to develop BOS.

Published
2018

11. Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)

Author

Vincent Dunet, Nicole Aebsicher, Emmanuel Deshayes, Patrick Yerly, John-David Aubert, Maura Prella, Periklis Mitsakis, Nicod Laurent, and John O. Prior

Subjects
Pressure overload, medicine.medical_specialty, Lung, business.industry, Haemodynamic response, Endothelin receptor antagonist, Bosentan, Pulmonary function testing, medicine.anatomical_structure, Ventricle, Internal medicine, medicine, Cardiology, Vascular resistance, business, medicine.drug
Abstract

Introduction: ERA in PAH and CTEPH patients with compromised lung and heart function produces hemodynamic response in pulmonary vascular resistance. Cardiac FDG-PET measures glucose metabolism reflecting pressure overload in the right ventricle (RV) as compared to the left ventricle (LV). Aims: We measured ERA effect in PAH and CTEPH on RV glucose metabolism as surrogate of cardiac wall stress. Methods: Bosentan (2´62.5mg/d for 4w, then 2´125mg/d) was instituted in therapy-naive patients undergoing 3 FDG-PET scans (0, 6, and 12w) with PET-measured RV/LV activity ratio. At each visit, pulmonary function testing, 6-min walk test, NT-proBNP and cardiac echography were assessed. Results: We enrolled 2 NYHA-III patients (1 PAH aged 67y, 1 CTEPH aged 55y), who clinically responded by the 6-min walk test, NT-proBNP and cardiac echography. The RV/LV uptake ratio decreased after therapy initiation (Figure, p=0.03) towards normalization (N 15mm, p=0.3). Conclusions: FDG-PET imaging may help disease monitoring and therapy management of impending RV dysfunction in high-risk patients. This cardiac imaging metrics could be of interest in trials studying the therapeutic effect of ERA on PAH and CTEPH.

Published
2017

12. Development of a multivariate prediction model for early-onset bronchiolitis obliterans syndrome and restrictive allograft syndrome in lung transplantation

Author

Koutsokera, Angela, Royer, Pierre J., Antonietti, Jean P., Fritz, Andreas, Benden, Christian, Aubert, John D., Tissot, Adrien, Botturi, Karine, Roux, Antoine, Reynaud-Gaubert, Martine L., Kessler, Romain, Dromer, Claire, Mussot, Sacha, Mal, Herve, Mornex, Jean-Francois, Guillemain, Romain, Knoop, Christiane, Dahan, Marcel, Soccal, Paola M., Claustre, Johanna, Sage, Edouard, Gomez, Carine, Magnan, Antoine, Pison, Christophe, Nicod, Laurent P., Chung, Kian, Wewers, Mark, Hillerdal, Gunnar, Division of Pulmonary Medicine, Medical University Vienna, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Biomax Informatics AG, Division Pulmonary Medicine, University hospital of Zurich [Zurich], UPRES EA220, Service de Pneumologie, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), UPRES EA220, Lung Transplantation Department, Lung Transplantation Center, Hôpitaux Universitaires de Strasbourg, Service Maladies Respiratoires, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux]-CHU Bordeaux [Bordeaux], Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardiopulmonaire, Hôpital Marie Lannelongue, INSERM UMR1152, Service de Pneumologie et Transplantation Pulmomaire, Hôpital Bichat - Claude Bernard, Assistance Publique - Hôpitaux de Paris (AP-HP), Rétrovirus et Pathologie Comparée (RPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL), Department of Chest Medicine, Mont-Godinne Hospital-Catholic University of Louvain de Mont-Godinne, Hop Larrey, Geneva University Hospital (HUG), Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, Centre Hospitalier Universitaire de Grenoble, UPRES EA220, Thoracique Surgery Department, Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Université Grenoble Alpes (UGA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF), Centre Hospitalier Universitaire [Grenoble] (CHU), Nantes Metropole, Region Pays de la Loire, Swiss National Science Foundation, Swiss University Hospitals G15, Swiss National Research Foundation 3347CO-108795, ANR-10-IBHU-0005/10-IBHU-0005,CESTI (TSI-IHU),CESTI (TSI-IHU)(2010), European Project: 305457,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,SYSCLAD(2012), SysCLAD Consortium, De Geest, Sabina, Koutsokera, Angela, Medizinische Universität Wien = Medical University of Vienna, Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Hôpital Marie-Lannelongue, Institut National de la Recherche Agronomique (INRA)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), ANR-10-IBHU-0005,CESTI (TSI-IHU),Centre Européen des Sciences de la Transplantation et de l'Immunothérapie (TSI-IHU)(2010), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], ProdInra, Archive Ouverte, Instituts Hospitalo-Universitaires B - Centre Européen des Sciences de la Transplantation et de l'Immunothérapie (TSI-IHU) - - CESTI (TSI-IHU)2010 - ANR-10-IBHU-0005 - IBHU - VALID, Systems prediction of Chronic Lung Allograft Dysfunction - SYSCLAD - - EC:FP7:HEALTH2012-11-01 - 2014-10-31 - 305457 - VALID, and Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA)

Subjects
medicine.medical_treatment, [SDV]Life Sciences [q-bio], bronchiolitis obliterans syndrome, 030230 surgery, Logistic regression, predictive model, 0302 clinical medicine, chronic lung allograft dysfunction, restrictive allograft syndrome, chronic rejection, Original Research, ddc:616, lcsh:R5-920, MINIMAL ACUTE REJECTION, Interstitial lung disease, Immunosuppression, General Medicine, humanities, 3. Good health, [SDV] Life Sciences [q-bio], medicine.anatomical_structure, Cohort, SURVIVAL, HEART, Medicine, lcsh:Medicine (General), Life Sciences & Biomedicine, medicine.medical_specialty, Bronchiolitis obliterans, DIAGNOSIS, transplantation pulmonaire, 03 medical and health sciences, Medicine, General & Internal, INTERNATIONAL-SOCIETY, Internal medicine, General & Internal Medicine, medicine, Lung transplantation, Lung, Science & Technology, business.industry, Généralités, medicine.disease, DYSFUNCTION, Surgery, modèle prédictif, Institutional repository, 030228 respiratory system, REGISTRY, RISK-FACTORS, allogreffe, business, LYMPHOCYTIC BRONCHIOLITIS, BASILIXIMAB
Abstract

Background: Chronic lung allograft dysfunction and its main phenotypes, bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), are major causes of mortality after lung transplantation (LT). RAS and early-onset BOS, developing within 3 years after LT, are associated with particularly inferior clinical outcomes. Prediction models for early-onset BOS and RAS have not been previously described. Methods: LT recipients of the French and Swiss transplant cohorts were eligible for inclusion in the SysCLAD cohort if they were alive with at least 2 years of follow-up but less than 3 years, or if they died or were retransplanted at any time less than 3 years. These patients were assessed for early-onset BOS, RAS, or stable allograft function by an adjudication committee. Baseline characteristics, data on surgery, immunosuppression, and year-1 follow-up were collected. Prediction models for BOS and RAS were developed using multivariate logistic regression and multivariate multinomial analysis. Results: Among patients fulfilling the eligibility criteria, we identified 149 stable, 51 BOS, and 30 RAS subjects. The best prediction model for early-onset BOS and RAS included the underlying diagnosis, induction treatment, immunosuppression, and year-1 class II donor-specific antibodies (DSAs). Within this model, class II DSAs were associated with BOS and RAS, whereas pre-LT diagnoses of interstitial lung disease and chronic obstructive pulmonary disease were associated with RAS. Conclusion: Although these findings need further validation, results indicate that specific baseline and year-1 parameters may serve as predictors of BOS or RAS by 3 years post-LT. Their identification may allow intervention or guide risk stratification, aiming for an individualized patient management approach., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

16. Respirez le bon air!

Author

Gasche-Soccal, Paola Marina Alessandra and Nicod, Laurent P.

Subjects
ddc:616, Respiratory Tract Diseases/epidemiology, Humans, Air Pollution/adverse effects
Published
2016

17. Long-term data from the Swiss pulmonary hypertension registry

Author

Fellrath, Jean-Marc, Weilenmann, Daniel, Speich, Rudolf, Ulrich, Silvia, Aubert, John-David, Azzola, Andrea, Huber, Lars C, Hasler, Elisabeth, Geiser, Thomas, Rochat, Thierry, Keusch, Stephan, Beghetti, Maurice, Nicod, Laurent, Domeninghetti, Guido, Mueller-Mottet, Séverine, Lador, Frederic, Grendelmeier, Peter, Domenighetti, Guido, Tamm, Michael, Popov, Vladimir, Stricker, Hans, Schwerzmann, Markus, Schoch, Otto, and University of Zurich

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Adolescent, Combination therapy, Hypertension, Pulmonary, medicine.medical_treatment, Hemodynamics, 610 Medicine & health, Young Adult, Informed consent, Internal medicine, Epidemiology, medicine, Humans, Registries, Aged, Endarterectomy, ddc:616, ddc:618, business.industry, Middle Aged, medicine.disease, Pulmonary hypertension, 3. Good health, Surgery, Transplantation, 2740 Pulmonary and Respiratory Medicine, Long term data, Female, 10029 Clinic and Policlinic for Internal Medicine, 10178 Clinic for Pneumology, business, Switzerland
Abstract

Background: Registries are important for real-life epidemiology on different pulmonary hypertension (PH) groups. Objective: To provide long-term data of the Swiss PH registry of 1998-2012. Methods: PH patients have been classified into 5 groups and registered upon written informed consent at 5 university and 8 associated hospitals since 1998. New York Heart Association (NYHA) class, 6-min walk distance, hemodynamics and therapy were registered at baseline. Patients were regularly followed, and therapy and events (death, transplantation, endarterectomy or loss to follow-up) registered. The data were stratified according to the time of diagnosis into prevalent before 2000 and incident during 2000-2004, 2005-2008 and 2009-2012. Results: From 996 (53% female) PH patients, 549 had pulmonary arterial hypertension (PAH), 36 PH due to left heart disease, 127 due to lung disease, 249 to chronic thromboembolic PH (CTEPH) and 35 to miscellaneous PH. Age and BMI significantly increased over time, whereas hemodynamic severity decreased. Overall, event-free survival was 84, 72, 64 and 58% for the years 1-4 and similar for time periods since 2000, but better during the more recent periods for PAH and CTEPH. Of all PAH cases, 89% had target medical therapy and 43% combination therapy. Of CTEPH patients, 14 and 2% underwent pulmonary endarterectomy or transplantation, respectively; 87% were treated with PAH target therapy. Conclusion: Since 2000, the incident Swiss PH patients registered were older, hemodynamically better and mostly treated with PAH target therapies. Survival has been better for PAH and CTEPH diagnosed since 2008 compared with earlier diagnosis or other classifications.

Published
2015

18. Pulmonary biomarkers in COPD exacerbations: a systematic review

Author

Koutsokera, Angela Kostikas, Konstantinos Nicod, Laurent P. and Fitting, Jean-William

Abstract

Exacerbations of COPD (ECOPD) represent a major burden for patients and health care systems. Innovative sampling techniques have led to the identification of several pulmonary biomarkers. Although some molecules are promising, their usefulness in clinical practice is not yet established. Medline and Highwire databases were used to identify studies evaluating pulmonary sampled biomarkers in ECOPD. We combined 3 terms for ECOPD, 3 for biomarkers and 6 for the sampling method. Seventy-nine studies were considered eligible for inclusion in the review and were analyzed further. Pulmonary biomarkers sampled with non-invasive, semi-invasive and invasive methods were evaluated for their potential to illustrate the disease’s clinical course, to correlate to clinical variables and to predict clinical outcomes, ECOPD etiology and response to treatment. According to published data several pulmonary biomarkers assessed in ECOPD have the potential to illustrate the natural history of disease through the modification of their levels. Among the clinically relevant molecules, those that have been studied the most and appear to be promising are spontaneous and induced sputum biomarkers for reflecting clinical severity and symptomatic recovery, as well as for directing towards an etiological diagnosis. Current evidence on the clinical usefulness of exhaled breath condensate and bronchoalveolar lavage biomarkers in ECOPD is limited. In conclusion, pulmonary biomarkers have the potential to provide information on the mechanisms underlying ECOPD, and several correlate with clinical variables and outcomes. However, on the basis of published evidence, no single molecule is adequately validated for wide clinical use. Clinical trials that incorporate biomarkers in decisional algorithms are required.

Published
2013

19. Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease

Author

Perreau Matthieu, Rozot Virginie, Welles Hugh C., Belluti-Enders Felicitas, Vigano Selena, Maillard Michel, Dorta Gian, Mazza-Stalder Jesica, Bart Pierre-Alexandre, Roger Thierry, Calandra Thierry, Nicod Laurent, and Harari Alexandre

Subjects
CD4-Positive T-Lymphocytes, Receptors, CCR6, Receptors, CXCR3, Interleukin-17, Epitopes, T-Lymphocyte, Humans, Th17 Cells, Tuberculosis, chemical and pharmacologic phenomena, Mycobacterium tuberculosis, respiratory system, bacterial infections and mycoses, Bronchoalveolar Lavage Fluid
Abstract

Protective immunity to Mycobacterium tuberculosis (Mtb) is commonly ascribed to a Th1 profile; however, the involvement of Th17 cells remains to be clarified. Here, we characterized Mtb-specific CD4(+) T cells in blood and bronchoalveolar lavages (BALs) from untreated subjects with either active tuberculosis disease (TB) or latent Mtb infection (LTBI), considered as prototypic models of uncontrolled or controlled infection, respectively. The production of IL-17A, IFN-γ, TNF-α, and IL-2 by Mtb-specific CD4(+) T cells was assessed both directly ex vivo and following in vitro antigen-specific T-cell expansion. Unlike for extracellular bacteria, Mtb-specific CD4(+) T-cell responses lacked immediate ex vivo IL-17A effector function in both LTBI and TB individuals. Furthermore, Mtb-specific Th17 cells were absent in BALs, while extracellular bacteria-specific Th17 cells were identified in gut biopsies of healthy individuals. Interestingly, only Mtb-specific CD4(+) T cells from 50% of LTBI but not from TB subjects acquired the ability to produce IL-17A following Mtb-specific T-cell expansion. Finally, IL-17A acquisition by Mtb-specific CD4(+) T cells correlated with the coexpression of CXCR3 and CCR6, currently associated to Th1 or Th17 profiles, respectively. Our data demonstrate that Mtb-specific Th17 cells are selectively undetectable in peripheral blood and BALs from TB patients.

Published
2012

22. Infection latente à M. tuberculosis, mise à jour 2011

Author

Lechartier, Benoît, Mazza-Stalder, Jesica, Janssens, Jean-Paul, and Nicod, Laurent P

Subjects
ddc:616, Adult, Hematologic Tests, Models, Tuberculin Test, Mycobacterium tuberculosis/isolation & purification, Humans, Health Care Costs, Latent Tuberculosis/diagnosis/economics/epidemiology/therapy, Biological, Interferon-gamma Release Tests
Abstract

It is estimated that one third of the world population is latently infected by Mycobacterium tuberculosis and thus at risk of reactivation. Latent tuberculosis (TB) impact in Switzerland is often overlooked. Diagnosis and prophylaxis are insufficiently undertaken, especially for people at higher risk of reactivation due to immunosuppression. Interferon-gamma release assays replace tuberculosis skin tests for diagnosis of latent infection in adults. It is still recommended to treat prophylactically a case of latent TB infection with 9 months of isoniazid; however therapy with rifampicin for 4 months, currently an alternative option, is linked to improved adherence and favorable cost-benefit ratio.

Published
2011

23. BPCO et non-fumeur?

Author

Rochat, Thierry and Nicod, Laurent

Subjects
ddc:616, Smoking Cessation, Humans, Pulmonary Disease, Chronic Obstructive/*rehabilitation, Societies, Medical, United States
Published
2010

24. Immunology taught by lung dendritic cells

Author

von Garnier Christophe and Nicod Laurent P

Subjects
T-Lymphocytes, Respiratory System, Respiratory Tract Diseases, Humans, Dendritic Cells
Abstract

Dendritic cells (DCs) are leukocytes specialised in the uptake, processing, and presentation of antigen and fundamental in regulating both innate and adaptive immune functions. They are mainly localised at the interface between body surfaces and the environment, continuously scrutinising incoming antigen for the potential threat it may represent to the organism. In the respiratory tract, DCs constitute a tightly enmeshed network, with the most prominent populations localised in the epithelium of the conducting airways and lung parenchyma. Their unique localisation enables them to continuously assess inhaled antigen, either inducing tolerance to inoffensive substances, or initiating immunity against a potentially harmful pathogen. This immunological homeostasis requires stringent control mechanisms to protect the vital and fragile gaseous exchange barrier from unrestrained and damaging inflammation, or an exaggerated immune response to an innocuous allergen, such as in allergic asthma. During DC activation, there is upregulation of co-stimulatory molecules and maturation markers, enabling DC to activate naïve T cells. This activation is accompanied by chemokine and cytokine release that not only serves to amplify innate immune response, but also determines the type of effector T cell population generated. An increasing body of recent literature provides evidence that different DC subpopulations, such as myeloid DC (mDC) and plasmacytoid DC (pDC) in the lungs occupy a key position at the crossroads between tolerance and immunity. This review aims to provide the clinician and researcher with a summary of the latest insights into DC-mediated pulmonary immune regulation and its relevance for developing novel therapeutic strategies for various disease conditions such as infection, asthma, COPD, and fibrotic lung disease.

Published
2009

25. Epidemiology of pulmonary hypertension: new data from the Swiss registry

Author

Tueller, Claudia, Stricker, Hans, Gasche-Soccal, Paola Marina Alessandra, Tamm, Michael, Aubert, John-David, Maggiorini, Marco, Zwahlen, Marcel, and Nicod, Laurent

Subjects
ddc:616, Adult, Male, Registries/*statistics & numerical data, Survival Rate/trends, Pulmonary Wedge Pressure/physiology, Middle Aged, Severity of Illness Index, Switzerland/epidemiology, Humans, Female, Morbidity/trends, Prospective Studies, Hypertension, Pulmonary/*epidemiology/physiopathology
Abstract

BACKGROUND: since 1999 data from pulmonary hypertension (PH) patients from all PH centres in Switzerland were prospectively collected. We analyse the epidemiological aspects of these data. METHODS: PH was defined as a mean pulmonary artery pressure of >25 mm Hg at rest or >30 mm Hg during exercise. Patients with pulmonary arterial hypertension (PAH), PH associated with lung diseases, PH due to chronic thrombotic and/or embolic disease (CTEPH), or PH due to miscellaneous disorders were registered. Data from adult patients included between January 1999 and December 2004 were analysed. RESULTS: 250 patients were registered (age 58 +/- 16 years, 104 (41%) males). 152 patients (61%) had PAH, 73 (29%) had CTEPH and 18 (7%) had PH associated with lung disease. Patients 50 years (76% vs. 53%, p

Published
2008

26. Health-related quality of life following single or bilateral lung transplantation: a 7-year comparison to functional outcome

Author

Gerbase, Margaret, Spiliopoulos, Anastase, Rochat, Thierry, Archinard, Marc, and Nicod, Laurent

Subjects
ddc:616, Adult, Male, Pulmonary Emphysema/surgery, ddc:617, Recovery of Function, respiratory system, Middle Aged, Lung Diseases/surgery, Lung Transplantation/methods, respiratory tract diseases, Quality of Life, Humans, Female, Follow-Up Studies
Abstract

To compare long-term health-related quality of life (HRQL) in single and bilateral lung transplant recipients independent of the underlying disease, and in a subset of patients with native pulmonary emphysema.

Published
2005

28. Use of biologics in allergic and type 2 inflammatory diseases in the current Covid 19 pandemic(a, b, c)

Author

Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thohomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Akash Kothari, Matucci, Andrea, Palomares, Oscar, Szepfalusi, Zsolt, Pohl, Wolfgang, Hoetzenecker, Wolfram, Rosenkranz, Alexander R., Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Joerg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Moesges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus F., Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ringa, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Muelleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje-H, Horak, Fritz, Woehrl, Stefan, Niederberger-Leppin, Verena, Pali-Schoell, Isabella, Pohlg, Wolfgang, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Muebeccel, Matricardi, Paolo M., Spertini, Francois, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Juergen, O Mahony, Liam, Knol, Edward F., Del Giacco, Stefano, Chivato Perez, Tomas, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek

29. Microbiota Promotes Chronic Pulmonary Inflammation by Enhancing IL-17A and Autoantibodies

Author

Yadava, Koshika, Pattaroni, Céline, Sichelstiel, Anke K, Trompette, Aurélien, Gollwitzer, Eva S, Salami, Olawale, Von Garnier, Christophe, Nicod, Laurent P, and Marsland, Benjamin J

Subjects
610 Medicine & health, 3. Good health
Abstract

RATIONALE Changes in the pulmonary microbiota are associated with progressive respiratory diseases including chronic obstructive pulmonary disease. Whether there is a causal relationship between these changes and disease progression remains unknown. OBJECTIVE To investigate the link between an altered microbiota and disease, we utilized a model of chronic lung inflammation in specific pathogen free (SPF) mice and mice depleted of microbiota by antibiotic treatment or devoid of a microbiota (axenic). METHODS Mice were challenged with LPS/elastase intranasally over 4 weeks, resulting in a chronically inflamed and damaged lung. The ensuing cellular infiltration, histological damage and decline in lung function were quantified. MEASUREMENTS AND MAIN RESULTS Similar to human disease, the composition of the pulmonary microbiota was altered in disease animals. We found that the microbiota richness and diversity were decreased in LPS/Elastase-treated mice, with an increased representation of the genera Pseudomonas, Lactobacillus and a reduction in Prevotella. Moreover, the microbiota was implicated in disease development as mice depleted of microbiota exhibited an improvement in lung function, reduction in airway inflammation, decrease in lymphoid neogenesis and auto-reactive antibody responses. The absence of microbial cues also markedly decreased the production of IL-17A, whilst intranasal transfer of fluid enriched with the pulmonary microbiota isolated from diseased mice enhanced IL-17A production in the lungs of antibiotic treated or axenic recipients. Finally, in mice harboring a microbiota, neutralizing IL-17A dampened inflammation and restored lung function. CONCLUSIONS Collectively, our data indicate that host-microbial cross-talk promotes inflammation and could underlie the chronicity of inflammatory lung diseases.

Catalog

Books, media, physical & digital resources
See catalog results